Physician profile
Christopher Hunter
NPI 1871084525
$2,498.79
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,346 · 2022: $867 · 2023: $109 · 2024: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $285.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $507.38 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $338.54 | 2021-2023 | Farxiga |
| Amarin Pharma, INC. | $261.22 | 2021-2022 | |
| Novo Nordisk INC | $218.30 | 2021-2023 | Wegovy |
| Davol INC. | $157.34 | 2024 | Phasix Mesh |
| Takeda Pharmaceuticals U.S.A., INC. | $125.96 | 2021-2022 | |
| Glaxosmithkline, LLC. | $111.13 | 2021-2022 | |
| Lilly USA, LLC | $107.05 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.71 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $81.42 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $78.64 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $75.16 | 2021-2022 | |
| Pfizer INC. | $52.82 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $36.51 | 2022 | |
| Eisai INC. | $34.11 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $33.39 | 2023 | Cologuard Collection Kit |
| Dexcom, INC. | $32.27 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.65 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.59 | 2022 | |
| Ibsa Pharma INC. | $24.74 | 2021 | |
| Endo Pharmaceuticals INC. | $21.86 | 2021 | |
| Amgen INC. | $17.10 | 2021 | |
| Merck Sharp & Dohme LLC | $17.00 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.30 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.